• Editorial Board

    May 21, 2026, 11:08

  • Influence of Initial Imaging Modality on Peri-Diagnostic Outcomes Among Pancreatic, Liver, Ovarian, and Bladder Cancers Without Routine Screening Programs: A Surveillance, Epidemiology, and End Results-Medicare Study

    May 1, 2026, 00:00

  • Valuing Child Health: An EQ-5D-Y-3L Value Set for the United States

    May 1, 2026, 00:00

  • Technological Maturity and Cost-Effectiveness of Medical Artificial Intelligence: A Systematic Review of Health Economic Evaluations

    May 1, 2026, 00:00

  • Estimating Heterogeneous Treatment Effects With Real-World Health Data: A Scoping Review of Machine Learning Methods

    May 1, 2026, 00:00

  • Switching From EQ-5D-3L to EQ-5D-5L in England: The Impact in NICE Technology Appraisals

    May 1, 2026, 00:00

  • Assessing the Role of Presurgical Information on Patient-Reported Outcomes: A Causal Analysis

    May 1, 2026, 00:00

  • Welfare-Based Healthcare Planning: Methodology and Application to Thoracic Surgical Treatment of Lung Cancer in Germany

    May 1, 2026, 00:00

  • International Reference Pricing: Impact of Changing the Basket of Reference Countries on Ability to Reference and on Drug Launch Prices in 6 Markets

    May 1, 2026, 00:00

  • Methods for Evaluation of Surrogate Endpoints for Health Technology Assessment Decision Making: A Good Practices Report of an ISPOR Task Force

    May 1, 2026, 00:00

  • A Practical Method for Estimating Generalized Risk-Adjusted Cost-Effectiveness Utilities and Willingness-to-Pay Corrections

    May 1, 2026, 00:00

  • No Differential Item Functioning of Patient-Reported Outcomes Measurement Information System Global Health Items by Neighborhood Socioeconomic Deprivation

    May 1, 2026, 00:00

  • Accounting for the Scarcity of Time as Patients Approach End of Life: The Construction of End-Weighted Time Toxicity

    May 1, 2026, 00:00

  • Uncovering the Cost-Effectiveness of Theory-Based Implementation Approaches: A Health Economic Analysis of the Hide and Seek Project Trial

    May 1, 2026, 00:00

  • Syringe Services Participants’ Preferences for Wound Care, HIV/Hepatitis C Virus Screening, and Opioid Use Disorder Treatment: A Discrete Choice Experiment

    May 1, 2026, 00:00

  • Preferences for Neurodevelopmental Screening Modalities for Children: A Labeled Discrete Choice Experiment Using Partial Choice Set Design

    May 1, 2026, 00:00

  • Development of a Brief Personal Health Agency Measure Among Patients Seeking Discretionary Musculoskeletal Specialty Care

    May 1, 2026, 00:00

  • Author Reply

    May 1, 2026, 00:00

  • The Dark Side of the “Thousand-Faces” Vision: Ethical and Economic Reflections on Algorithmic Psychotherapy Matching

    May 1, 2026, 00:00

  • From Prediction to Optimization: Machine Learning-Driven Integration of the Health Economic Value Chain and Revolution in System Efficiency

    May 1, 2026, 00:00

  • A United Kingdom Value Set for the EQ-5D-5L

    May 1, 2026, 00:00

  • Applying the Argument-Based Approach to Validation With Clinical Outcome Assessments: Strategies for Constructing a Rationale

    May 1, 2026, 00:00

  • Table of Contents

    May 1, 2026, 00:00

  • Estimating the Global Macroeconomic Impact of Tuberculosis Among Children and Adolescents

    May 1, 2026, 00:00

  • Optimizing Decision Making in Universal Newborn Hearing Screening: A Value of Information Perspective

    May 1, 2026, 00:00

  • Editorial Board

    Apr 6, 2026, 13:15

  • From Consensus to Implementation: Advancing Patient-Centered Health Technology Assessment

    Apr 1, 2026, 00:00

  • How Good Is Good Enough? A Simulation Study of Adaptive Health Technology Assessment

    Apr 1, 2026, 00:00

  • Toward a Harmonized Health Technology Assessment Framework for Digital Health Technologies in Europe

    Apr 1, 2026, 00:00

  • Economic Evaluations of Orphan Drugs for Rare Kidney Diseases in Low- and Middle-Income Countries: A Bibliometric Systematic Review With Policy and Evidence Gaps Analysis

    Apr 1, 2026, 00:00

  • Evaluation of Health Technology Assessment Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access

    Apr 1, 2026, 00:00

  • Deepening and Broadening: Revisiting Theories, Long-Term Economic Impact, and Diversity in Parental Bereavement After the Loss of a Child to Spinal Muscular Atrophy

    Apr 1, 2026, 00:00

  • Table of Contents

    Apr 1, 2026, 00:00

  • Valuing Pediatric Technologies: A Framework for Parental Spillovers in Spinal Muscular Atrophy Bereavement

    Apr 1, 2026, 00:00

  • Decision Analytic Models to Assess the Cost-Effectiveness of Prevention, Detection, and Treatment in Multiple Long-Term Conditions: A Scoping Review

    Apr 1, 2026, 00:00

  • System-Wide Use of Patient-Reported Outcome Measures in Organization for Economic Co-operation and Development Countries: Insights From a Health Policy Survey and Key Informant Workshops

    Apr 1, 2026, 00:00

  • Author Reply

    Apr 1, 2026, 00:00

  • Reanalyzing Value Assessments in American Heart Association Clinical Practice Guidelines Using Health Years in Total Instead of Quality-Adjusted Life-Years

    Apr 1, 2026, 00:00

  • Author Reply

    Apr 1, 2026, 00:00

  • Valuing Child and Adolescent Health States to Derive Utilities for Use in Economic Evaluation: A Good Practices Report of an ISPOR Task Force

    Apr 1, 2026, 00:00

  • Impact of Heatwaves on Health-Related Quality of Life in Older Chinese Adults: A Longitudinal Cohort Study

    Apr 1, 2026, 00:00

  • A Forward Agenda for Digital Health Technologies: Evidence That Works for Decisions

    Apr 1, 2026, 00:00

  • Qini Curves for Potential Impact Assessment of Risk Predictive Models Informing Intervention Policies

    Apr 1, 2026, 00:00

  • A Systematic Review of the Methods and Quality of Economic Evaluations for Artificial-Intelligence-Assisted Cancer Screening or Diagnosis

    Apr 1, 2026, 00:00

  • Face Validation of an Artificial Intelligence Driven Tool for Clinical Triaging in Australian Public Oral Healthcare: A Pilot Study

    Apr 1, 2026, 00:00

  • Implications of Incorporating Environmental Sustainability Into Health Technology Assessment for Digital Health Technologies

    Apr 1, 2026, 00:00

  • Cost Savings and Improved Clinical Outcomes From a Mobile Health Cardiovascular Disease Self-Management Program

    Apr 1, 2026, 00:00

  • Exploring Methods to Include Carbon Emissions Into a Health Technology Assessment: The Case of Remote Patient Monitoring

    Apr 1, 2026, 00:00

  • A Patient-Level Simulation Tool to Inform Data-Driven Pain Treatment Decisions and Policy in the US Military Health System

    Apr 1, 2026, 00:00

  • Estimating the Shares of the Value of Branded Pharmaceuticals Accruing to Manufacturers and to Patients in the Thai Healthcare System

    Apr 1, 2026, 00:00

  • The Effect of Perspective, Duration, and Views on Death on the Valuation of Severe Health States

    Apr 1, 2026, 00:00

  • Editorial Board

    Mar 11, 2026, 10:20

  • Table of Contents

    Mar 1, 2026, 00:00

  • Return-on-Investment in Health Economic Evaluation: An Exploratory Analysis

    Mar 1, 2026, 00:00

  • Economic Evaluation of Deprescribing in Older Adults: A Systematic Review

    Mar 1, 2026, 00:00

  • Patient-Reported Outcome Measures in Clinical Trials: An Analysis of Trends From 2008 to 2023

    Mar 1, 2026, 00:00

  • Empirical Evidence and Conceptual Framework to Address the Indian Health Service Underfunding Challenge

    Mar 1, 2026, 00:00

  • Psychometric Performance of Skin, Self-Confidence, and Social Health-Related EQ-5D-5L Bolt-Ons in Patients With Atopic Dermatitis and Psoriasis in Germany

    Mar 1, 2026, 00:00

  • Reversing Proxy Roles: Care Recipients as Proxies for Caregiver Health-Related Quality of Life

    Mar 1, 2026, 00:00

  • Psychometric Properties of Cognition Bolt-Ons for the EQ-5D-3L and EQ-5D-5L: A Systematic Review

    Mar 1, 2026, 00:00

  • Comparative Effectiveness of Ixekizumab Versus Ustekinumab in Patients With Psoriasis: A Randomized Controlled Trial Replication Using Data From an Observational Study (Shanghai Psoriasis Effectiveness Evaluation Cohort)

    Mar 1, 2026, 00:00

  • The Uneven Path of Psychological Distress: How Socioeconomic Status Shapes Distress Transitions in Australian Adults

    Mar 1, 2026, 00:00

  • Genomic Testing in Australia: A Budget Impact Analysis Using Diffusion Modeling From a Healthcare System Perspective

    Mar 1, 2026, 00:00

  • Impact of China’s National Drug Price Negotiation Policy on Availability, Affordability, and Regional Equity of Negotiated Drugs: A Multidimensional Nationwide Analysis, 2018 to 2021

    Mar 1, 2026, 00:00

  • Health Utility Decrements Associated With Social Isolation and Loneliness: Evidence From Australian Longitudinal Data

    Mar 1, 2026, 00:00

  • Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care, and Well-Being Measures in the Context of Multiple Sclerosis

    Mar 1, 2026, 00:00

  • Author Reply

    Mar 1, 2026, 00:00

  • Disinvestment and Health Spending Efficiency in Latin America and the Caribbean: A Case Study of Colombia

    Mar 1, 2026, 00:00

  • Quantifying Accuracy and Cost in Public Preferences for Artificial Intelligence in Radiation Therapy

    Mar 1, 2026, 00:00

  • Priority for Self or Others? Incorporating Equity Considerations in a Preference-Based Health Value Assessment

    Mar 1, 2026, 00:00

  • Estimating the Willingness-to-Pay per Quality-Adjusted Life-Year to Aid Health Technology Assessment in India

    Mar 1, 2026, 00:00

  • Evaluating Long-Term Health Disparity Impacts of Clinical Algorithms Using a Patient-Level Simulation Framework

    Mar 1, 2026, 00:00

  • The Compounding Burden of Pregnancy Loss: A Longitudinal Analysis of Quality-of-Life Trajectories After Miscarriage

    Mar 1, 2026, 00:00

  • Hospital and Regional-Level Factors Associated With Negotiated Payer Rates for Hip Fracture Fixation: A Multistate Analysis

    Feb 1, 2026, 00:00

  • Should Early-Stage NIH Funding Influence Pharmaceutical Drug Pricing?

    Feb 1, 2026, 00:00

  • Cost-Effectiveness of Reorganizing the Approach to Diabetes Through the Application of Registries: An Innovative Model to Organize Diabetes Care in First Nations Communities in Canada

    Feb 1, 2026, 00:00

  • Means Can Be Deceiving: Comparing and Contrasting Risk Tolerance Estimates From a Discrete-Choice Experiment and a Threshold Technique Exercise

    Feb 1, 2026, 00:00

  • Derivation of Meaningful Change Thresholds for European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 in Patients With Small-Cell Lung Cancer

    Feb 1, 2026, 00:00

  • EQ-5D-5L in Multiple Sclerosis: Estimated Utility Values, Minimal (Clinically) Important Changes, and Direct and Indirect Influences Over Time

    Feb 1, 2026, 00:00

  • What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective

    Feb 1, 2026, 00:00

  • The Cost-Effectiveness of Community Health Workers in Primary Health Care: A Systematic Review

    Feb 1, 2026, 00:00

  • Preferences for Adopting Artificial Intelligence in Radiation Therapy Treatment: A Discrete Choice Experiment

    Feb 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children With Asthma

    Feb 1, 2026, 00:00

  • Mapping Methodologies for Economic Evaluation of Digital Health Technologies: A Scoping Review

    Feb 1, 2026, 00:00

  • A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making

    Feb 1, 2026, 00:00

  • Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Special Interest Group Report

    Feb 1, 2026, 00:00

  • PROM-ising Progress? Trends in Patient- and Clinician-Reported Outcome Measures in US Food and Drug Administration Orphan Drug Labels

    Feb 1, 2026, 00:00

  • Comparing Psychometric Properties of 6 of the 5-Level and 3-Level EQ-5D Bolt-Ons in a Large, Multinational, Longitudinal General Population Sample

    Feb 1, 2026, 00:00

  • How Do Different Health States Impact Preferences for Social-Care-Related Quality of Life: An Exploration of EQ-5D-5L and Adult Social Care Outcomes Toolkit Using a Vignette Approach

    Feb 1, 2026, 00:00

  • Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular Atrophy

    Feb 1, 2026, 00:00

  • Long-Term Outcomes and Cost-Effectiveness of Artificial Intelligence for Breast Cancer Screening: A Modeling Study

    Feb 1, 2026, 00:00

  • Development of a Preference Weighting System for the Parent-Proxy Child Chronic Cough Quality-of-Life Instrument

    Feb 1, 2026, 00:00

  • Editorial Board

    Jan 23, 2026, 08:45

  • Table of Contents

    Jan 23, 2026, 08:41

  • Table of Contents

    Jan 5, 2026, 12:03

  • Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions

    Jan 1, 2026, 00:00

  • The Cost-Effectiveness of Collagenase Injection Versus Limited Fasciectomy for Moderate Dupuytren’s Contracture: An Economic Evaluation of the Dupuytren’s Interventions Surgery Versus Collagenase Trial and a Decision Analytical Model

    Jan 1, 2026, 00:00

  • Adult Social Care Outcomes Toolkit and ICEpop Capability Measure in Decision Making: A Review of NICE Social Care and Public Health Guidelines

    Jan 1, 2026, 00:00

  • Unlocking Patient Preferences: The Potential of Stated-Preference Methods in Clinical Decision Making

    Jan 1, 2026, 00:00

  • Comparing Adolescent and Adult Preferences for EQ-5D-Y-3L Health States in Hong Kong

    Jan 1, 2026, 00:00

  • Health Inequality Aversion in the United States

    Jan 1, 2026, 00:00

  • Methodological Insights From Health Valuation Studies in Low- and Middle-Income Countries: A Scoping Review

    Jan 1, 2026, 00:00

  • Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries

    Jan 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children Aged 8 to 18 Years With Eczema

    Jan 1, 2026, 00:00

  • Predicting Healthcare Utilization Outcomes With Artificial Intelligence: A Large Scoping Review

    Jan 1, 2026, 00:00

  • A Generalized Risk-Adjusted Cost-Effectiveness Economic Model for Measuring the Value of Interventions That Delay Mobility Impairment Across Neurological Conditions

    Jan 1, 2026, 00:00

  • Toward a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report

    Jan 1, 2026, 00:00

  • Implications of Value Set Choice on EQ-5D-Y-3L Child and Proxy Health-Related Quality of Life Ratings: What to Do When a Country-Specific “Y” Value Set Is Unavailable?

    Jan 1, 2026, 00:00

  • Incorporating Informal Caregiving Time Into Cost-Effectiveness Analysis for Adults Aged 50 and Older: Estimating From Health-Related Quality of Life and Functional Status

    Jan 1, 2026, 00:00

  • Integrating Price Benchmarks and Comparative Clinical Effectiveness to Predict Initial Price Offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027)

    Jan 1, 2026, 00:00

  • Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program

    Jan 1, 2026, 00:00

  • Editorial Board

    Jan 1, 2026, 00:00

  • Clinical Outcomes and Measures for Vaginal Relaxation Syndrome: A Systematic Review

    Jan 1, 2026, 00:00

  • Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds

    Jan 1, 2026, 00:00

  • Operationalizing Distributional Cost-Effectiveness in Genomic Medicine: A United States–Focused Comment

    Jan 1, 2026, 00:00

  • Disclaimer

    Dec 19, 2025, 11:50

  • Editorial Board

    Dec 16, 2025, 09:49

  • RWD96 Health-Related Quality of Life in Adults With Dry Eye Disease in Fran Insights From a Multicenter Observational Study

    Dec 1, 2025, 00:00

  • MSR2 A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa

    Dec 1, 2025, 00:00

  • EE676 Surviving but Not Earning? Long-term Income Trajectories in Working-Age mIDH Glioma Patients: Stratification by Radiotherapy/Chemotherapy Exposure

    Dec 1, 2025, 00:00

  • MT23 Health Economic Evaluation Model for Breast Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • CO26 Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies

    Dec 1, 2025, 00:00

  • EE737 Treatment Patterns of Rare Immunodeficiencies With Special Regard to Antibiotics: A German Claims Data Analysis

    Dec 1, 2025, 00:00

  • HTA361 What Did Time Reveal Evaluating the Accuracy of Parametric Model Predictions Against Long-Term Observed Data for Larotrectinib?

    Dec 1, 2025, 00:00

  • EE85 Budget Impact Analysis of GLP-1 Receptor Agonists for Type 2 Diabetes Management in India

    Dec 1, 2025, 00:00

  • P9 Exploring Variability in EQ VAS Scores: A Systematic Review and Meta-Regression of Population Health Studies

    Dec 1, 2025, 00:00

  • PCR84 Evaluating the Role of Patient-Reported Outcomes in Phase 4 Clinical Trials: Trends, Applications, and Implications for Postmarketing Surveillance

    Dec 1, 2025, 00:00

  • EE328 Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework

    Dec 1, 2025, 00:00

  • HTA334 The Uptake of R in NICE HTA: Insights From Technology Assessment Groups

    Dec 1, 2025, 00:00

  • CO53 Comparative Effectiveness of Alectinib vs. Crizotinib as First-Line Therapy in ALK-Positive Non-Small Cell Lung Cancer: A Real-World Quasi-Experimental Study

    Dec 1, 2025, 00:00

  • HTA307 Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany

    Dec 1, 2025, 00:00

  • EPH193 Prevalence of Post-Traumatic Stress Disorder Among Ambulance Officers During the COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • EE442 Evaluating the Economic Impact of Worksite Physical Activity Interventions in Denmark: An Employer’s Perspective

    Dec 1, 2025, 00:00

  • MT2 Adoption of AI Clinical Decision Support Systems in Primary Care: An Evaluation of Physician Acceptance

    Dec 1, 2025, 00:00

  • EPH44 Chronic Kidney Disease in Type-2 Diabetes Patients: A Population-Based Descriptive Study

    Dec 1, 2025, 00:00

  • CO40 Characterization of the Distribution of Body Mass Index in Portuguese People With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • EPH254 The Role of Body Fat in the Regulation of Male Fertility

    Dec 1, 2025, 00:00

  • EE20 A Method to Estimate Causally Related Cost Savings of a Preventive Intervention: An Analysis Using the Wellness-Star∗ Database

    Dec 1, 2025, 00:00

  • HTA151 From French Early Access to Regular Reimbursement: How Do Prices Shift Post-HTA?

    Dec 1, 2025, 00:00

  • EE308 Cost-Utility Analysis of Standard-Dose vs. High-Dose Influenza Vaccination in Adults Aged ≥ 65 Years in Italy

    Dec 1, 2025, 00:00

  • EPH43 Characterizing Polycystic Ovary Syndrome (PCOS) and Related Diagnoses Using a Large US Electronic Health Records Database Linked to Claims, 2020-2025

    Dec 1, 2025, 00:00

  • HTA15 A Review of Utility Data Used in Health Technology Assessments From the Perspective of a Health Technology Assessment Body

    Dec 1, 2025, 00:00

  • HTA73 Challenges in the German AMNOG Procedure: The Need for National PICO Transparency and Optimized Consultation Windows in the Context of EU-HTA

    Dec 1, 2025, 00:00

  • EE143 Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain

    Dec 1, 2025, 00:00

  • SA95 The Journey to Diagnosis for Patients With CIDP: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • MSR7 A New Regulatory-Grade Chronic Disease Cohort Simulator: Leveraging the Large, Deep, and Long Constances Cohort Linked and Matched to the SNDS in France

    Dec 1, 2025, 00:00

  • EE496 Healthcare and Economic Burden of Intravenous and Subcutaneous Immunoglobulin Treatment in Three Autoimmune Neuromuscular Diseases: A Bicentric Spanish Experience

    Dec 1, 2025, 00:00

  • MSR161 Overfitting Mitigation in Neural Networks: Could Ergodic Regularization Be the Future of AI?

    Dec 1, 2025, 00:00

  • HTA102 Decoding the Future: How Are HTA Agencies Evaluating AI in Healthcare?

    Dec 1, 2025, 00:00

  • MSR222 What Prompt Engineering Missed and How Context Engineering Fixes It

    Dec 1, 2025, 00:00

  • EE327 Development of a Discrete Event Simulation Model to Explore the Potential Cost-Effectiveness for Cancer Early Detection Testing in Female BRCA Carriers

    Dec 1, 2025, 00:00

  • P4 Simulating Sponsor-HTA Conversations: A Multi-Agent GenAI Framework for Reimbursement Processes

    Dec 1, 2025, 00:00

  • HPR173 Regulatory Landscape Challenges and Trends in the Adoption of Digital Endpoints in Clinical Trials: A Scoping Review

    Dec 1, 2025, 00:00

  • Poor Patient Care Outcomes and Nurse Job Outcomes Associated With Unfavorable Intensive Care Unit and Emergency Department Nurse Work Environments: Implications for Critical Care Medicine

    Dec 1, 2025, 00:00

  • HPR27 Annual Change in Türkiye’s Reimbursement List: A Comparative Descriptive Analysis of the 2023 and 2024 SUT Annex 4-A Lists

    Dec 1, 2025, 00:00

  • RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care

    Dec 1, 2025, 00:00

  • EE154 Correlation Between Ultra-Orphan Drug Costs Cost-Effectiveness Metrics and Disease Prevalence

    Dec 1, 2025, 00:00

  • EE203 Cost-Effectiveness Analysis of Health2Sync Application With Patient Management Program Compared to Traditional Care for Patients With Type 2 Diabetes Mellitus in Taiwan

    Dec 1, 2025, 00:00

  • EE482 Half-Cycle Correction: It’s Time to Let It Go

    Dec 1, 2025, 00:00

  • HSD43 Environmental Impact of Intravenous vs. Oral Chemotherapy in Fran A 1000-Patient Model-Based Assessment

    Dec 1, 2025, 00:00

  • EE392 Economic Evaluations of Individual Service and Training Interventions for Self-Harm and Suicide Prevention: A Systematic Review

    Dec 1, 2025, 00:00

  • EE309 Cost-Utility Analysis of the AlloMap® Test for the Monitoring of Patients After Heart Transplantation: Economic Evaluation Alongside the CUPIDON Trial

    Dec 1, 2025, 00:00

  • MSR42 Automating PICOs Criteria Assessment in Systematic Reviews With LLMs: Insights From Two Case Studies

    Dec 1, 2025, 00:00

  • HTA362 What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques

    Dec 1, 2025, 00:00

  • CO208 Real-World Outcomes From a Pharmacy-Based Awareness and Screening Campaign for HF and CKD: Insights From the Chronic Diseases From A to Z Program

    Dec 1, 2025, 00:00

  • OP13 Knowledge of Natural Contraception and Its Effect on the Relationship: Mobile Application

    Dec 1, 2025, 00:00

  • HPR184 Single-Arm Trials and Reimbursement Decision Making in Europe: A Case Study in Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • EPH130 Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends

    Dec 1, 2025, 00:00

  • EPH150 Is Europe and European Evidence Development an Afterthought in Pharmaceutical Early Stage Development Decisions? An Exploratory Qualitative Survey

    Dec 1, 2025, 00:00

  • CO155 Inter-Version Comparison of the Boston Carpal Tunnel Questionnaire: A Clinical Validation Study of the Decision Tree-Based Version

    Dec 1, 2025, 00:00

  • EE486 Healthcare Resource Utilization and Costs Among Various Disease States in Adults With Hepatitis Delta Virus in Inpatient and Outpatient Settings in the United States

    Dec 1, 2025, 00:00

  • HTA24 Adoption and Evidence Generation in NICE Early Value Assessments (EVA) for Medtech: Trends Across 2023-2025

    Dec 1, 2025, 00:00

  • MT28 Impact of RFID-Enabled Unit-Level Traceability on Resource Utilization and Quality Assurance in Prefilled Syringe Production

    Dec 1, 2025, 00:00

  • CO142 Impact of Tafamidis Use in Colombian Patients Diagnosed With ATTR-CM on Health-Related Quality of Life During One Year of Follow-up: Real-World Study in Colombia

    Dec 1, 2025, 00:00

  • RWD6 A Record-Level Risk Metric for Partially Synthetic Clinical Data Using Inverse-Square Similarity Decay

    Dec 1, 2025, 00:00

  • HTA332 The Soft Science in Hard Decisions: Utility of Qualitative Evidence in HTA Decisions

    Dec 1, 2025, 00:00

  • EPH202 Quantifying the Economic Burden of Undiagnosed Sleep Apnea in India’s Productive Population: A Health Economic Modeling Approach

    Dec 1, 2025, 00:00

  • EE292 Cost-Savings Analysis of Fitusiran Prophylaxis: Reducing Breakthrough Bleeding Treatment Expenditure in the Kingdom of Saudi Arabia

    Dec 1, 2025, 00:00

  • EE44 All-Cause Healthcare Resource Use in Recurrent Respiratory Papillomatosis: A Claims-Based Comparison With Matched Controls

    Dec 1, 2025, 00:00

  • SA36 Economic Burden Utilities and Cost-Effectiveness of Perioperative Immunotherapies for Early Stage Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE179 Cost of Care for Relapsing/Remitting Multiple Sclerosis Treatments: A Pharmacoeconomic Evaluation From the Spanish Healthcare System Perspective

    Dec 1, 2025, 00:00

  • EPH249 The Incidence, Mortality, and Survival of Nonmetastatic Colorectal Cancer (CRC) per TNM Stages in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • PCR147 Is There a Lack of Dietary Data Collection in Real-World IBD Studies? Literature Review and Future Considerations

    Dec 1, 2025, 00:00

  • RWD60 Development and Implementation of a Dynamic Framework for Assessment and Improvement of Registries’ Data Quality

    Dec 1, 2025, 00:00

  • EE509 Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry Study

    Dec 1, 2025, 00:00

  • P52 Evolution of Risk-Sharing Agreements for Orphan Drugs 2015-2024

    Dec 1, 2025, 00:00

  • EPH192 Prevalence of Obesity and Comorbidities Among People With Obesity in China, Japan, and EU5

    Dec 1, 2025, 00:00

  • CO102 Estimating the Mean Time in Treatment-Free Remission for Patients in Early Line CML

    Dec 1, 2025, 00:00

  • HPR9 A Review of the UK's International Recognition Procedure and Its Role in Expediting Access to Innovative Treatments

    Dec 1, 2025, 00:00

  • MSR91 Evaluating Bayesian Borrowing Methods for Treatment Effect Extrapolation: A Simulation-Based Study

    Dec 1, 2025, 00:00

  • EE666 Socioeconomic Burden (SOB) of Multiple Sclerosis (MS) in Latin America (LATAM): Trends and Projections 2017-2032

    Dec 1, 2025, 00:00

  • PCR180 Patient Preferences for Type 2 Diabetes Mellitus (T2DM) Treatment: A Systematic Review of Discrete Choice Experiments Studies

    Dec 1, 2025, 00:00

  • HPR138 Market Access Challenges for Oncology Combination Therapies in Europe: A Review of Regulatory Approvals HTA Outcomes and Pricing Dynamics

    Dec 1, 2025, 00:00

  • RWD28 Characteristics of Patients Treated With Biologic Agents for Moderate-to-Severe Atopic Dermatitis in Poland

    Dec 1, 2025, 00:00

  • HPR47 Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and Fran Lessons for Poland

    Dec 1, 2025, 00:00

  • HTA32 Analysis of Pros Included in the HTA Assessment of Conditionally Approved Oncology Drugs in the UK, Italy, and Germany

    Dec 1, 2025, 00:00

  • HTA279 Reassessing NICE's Highly Specialized Technologies (HST) Criteria: A Retrospective Review of Borderline and Approved Appraisals Under the Revised Framework

    Dec 1, 2025, 00:00

  • EPH56 Delta Price Cost-Effectiveness Analysis of PCV21 vs. PCV20 Use in Adults Aged ≥18 Years in Austria

    Dec 1, 2025, 00:00

  • CO234 The Association of Glucagon-Like Peptide-1 Receptor Agonists With Hepatopancreatobiliary Diseases in Individuals With Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • HTA219 Level of ICER of Health Economic Assessment in France in 2024

    Dec 1, 2025, 00:00

  • MSR9 A Retrieval-Augmented Generation (RAG)-Based Framework to Automate Report Writing for Systematic Literature Reviews (SLRs) in Evidence Synthesis

    Dec 1, 2025, 00:00

  • EE64 Assessing the Value of Purewick™ System for the Management of Female Patients With Urinary Incontinence in the Nonacute Setting: Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • RWD152 Real-World Evidence From Community Oncology: Assessing Secular Trends in Ovarian Cancer Diagnoses From 2014 to 2024

    Dec 1, 2025, 00:00

  • HSD97 Real-World Treatment Patterns Among Patients With Relapsed or Refractory (R/R) NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US)

    Dec 1, 2025, 00:00

  • RWD31 Characterization of a Large-Scale Real-World Data Sour Impact of Linking Closed Claims With Electronic Health Record Data

    Dec 1, 2025, 00:00

  • EE678 Systematic Review of Decision-Analytic Models Estimating the Economic Impact of Prescription Opioid Use and Associated Adverse Events

    Dec 1, 2025, 00:00

  • HTA168 Harmonization or Hindrance? A Strategic Analysis of Divergent National Requirements Under the EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • HTA350 Use of Data From Phase 3 RCTs in Earlier Lines of Therapy in Support of Noncomparative Evidence From Pivotal Phase 2 Studies

    Dec 1, 2025, 00:00

  • HPR134 Maintaining Orphan Drug Status at the Time of Drug Approval in European Economic Area (EEA): European Union (EU) Plus Iceland and Norway From 2015 to 2025

    Dec 1, 2025, 00:00

  • EE391 Economic Evaluations of First-Line Non-Small Cell Lung Cancer Therapies: A Systematic Review With Focus on PD-L1 Subgroups

    Dec 1, 2025, 00:00

  • RWD63 Development of an LLM-Based Computable Phenotype for Pediatric Lymphoma Subtypes Using Structured and Unstructured Electronic Medical Record Data

    Dec 1, 2025, 00:00

  • EE19 A Health Economic Evaluation of Daylight: A Digital Treatment for Anxiety in NHS South Yorkshire

    Dec 1, 2025, 00:00

  • HPR19 Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis

    Dec 1, 2025, 00:00

  • CO199 Real Option Value of Sotatercept in Pulmonary Arterial Hypertension: A Health Economic Perspective on Future Treatment Opportunities

    Dec 1, 2025, 00:00

  • HTA64 Canadian HTA Decisions (2020-2023): Comparing CDA-AMC and INESSS Recommendations on Drug Reimbursement

    Dec 1, 2025, 00:00

  • SA28 Decoding Diagnosis Delay in Juvenile Idiopathic Arthritis (JIA)

    Dec 1, 2025, 00:00

  • HTA54 Beyond RCTs: The Role of Patient Perspectives and Nontraditional Evidence in HTA Decisions for Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • SA105 Where Is AI in Evidence Synthesis for NICE HTA Submissions?

    Dec 1, 2025, 00:00

  • RWD18 Archival Sample Testing for Real-World Insights: Innovative Approaches to Enriching Retrospective Studies With Biomarker Data

    Dec 1, 2025, 00:00

  • EE79 Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States (US)

    Dec 1, 2025, 00:00

  • EPH92 Evaluating Performance of the Experimental EQ-TIPS (V3) for Assessing Infants and Toddlers With Acute Infections: A Mixed-Methods Approach of Cognitive Debriefing and Psychometric Testing

    Dec 1, 2025, 00:00

  • CO108 Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

    Dec 1, 2025, 00:00

  • EPH205 Real-World Treatment Patterns of Trofinetide in Rett Syndrome: Analysis of Medical Pharmacy-Linked Claims Database in the United States

    Dec 1, 2025, 00:00

  • EE204 Cost-Effectiveness Analysis of Image-Guided Ablation vs. Conventional Ablation in Patients With Recurrent Ventricular Tachycardia: Results From the inEurHeart Trial

    Dec 1, 2025, 00:00

  • PCR257 Uptake and Early Removal of Hormonal Implant Contraceptive Among Women Attending the Family Planning Clinic in a Tertiary Institution in West Africa January 2018-December 2020

    Dec 1, 2025, 00:00

  • EPH185 Predictors of Effectiveness of Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis

    Dec 1, 2025, 00:00

  • EPH189 Prevalence of Meningococcal Carriage by Serogroup in Adolescents and Young Adults: A Global Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA139 Evolution of Acceptance of Evidence and PMA Outcomes by HTA Authorities for ATMPs in the EU4 and the UK 2017-2025

    Dec 1, 2025, 00:00

  • CO128 Health Technology Assessment, Reimbursement, and Funding Landscape Challenges for Oncology Companion Diagnostics in Europe and Canada

    Dec 1, 2025, 00:00

  • PT41 Health Economic Evaluations of Prevention and Management Strategies for Cholangiocarcinoma: A Systematic Review

    Dec 1, 2025, 00:00

  • RWD185 Trends and Disparities in Prostate Cancer Incidence Prevalence and Survival: A SEER Analysis 2000-2022

    Dec 1, 2025, 00:00

  • HTA86 Comprehensive Clinical Evaluation of Amphotericin B in the Treatment of Invasive Fungal Disease in China

    Dec 1, 2025, 00:00

  • PCR66 Domain Attrition in the IWQOL Series and the Challenges of Factor-Only Item Reduction

    Dec 1, 2025, 00:00

  • HTA116 The Challenges of Evaluating Individualized Therapies in Health Technology Assessment: A Thematic Review

    Dec 1, 2025, 00:00

  • CO85 Effectiveness of Inclisiran and Evolocumab in LDL-C Goal Attainment: A Hybrid Decision Tree-Markov Model Analysis

    Dec 1, 2025, 00:00

  • MSR217 Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-Term Treatment Effect: An Example in Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EE379 Economic Evaluation of Dinutuximab Beta in the Maintenance Therapy of High-Risk Neuroblastoma in Brazil

    Dec 1, 2025, 00:00

  • RWD172 Sex Differences in Characteristics and Treatment Patterns of Patients With Sleep Disorders in South Korea

    Dec 1, 2025, 00:00

  • EE633 Real-World Cost of Automated Red Blood Cell Exchange for Sickle Cell Disease in Kenya: A Cost-Reimbursement Gap Analysis From a Public Sector Perspective

    Dec 1, 2025, 00:00

  • HPR14 Access and Evolving Eviden A European HTA Analysis of Innovative Medicines Under Evidence Generation Agreements

    Dec 1, 2025, 00:00

  • SA82 Real-World Findings From the Provent Study of Dupilumab Therapy for Severe Asthma: 2-Year Analysis

    Dec 1, 2025, 00:00

  • CO250 Therapeutic Benefit of Radiotherapy in Uterine Serous Carcinoma (USC): A Real-World Study

    Dec 1, 2025, 00:00

  • EE147 Complement C5 Inhibitor (Anti-C5) and Neonatal Fc Receptor Antagonist Anti-FcRn in Myasthenia Gravis at University Public Hospitals of Paris, France (AP-HP): What Is the Market Share of These New Treatments?

    Dec 1, 2025, 00:00

  • EPH172 Objective Real-World Caregiver Costs and Lost Time for Absences and Family Medical Leaves in the United States for Employees Whose Spouses Have Dementia and/or Alzheimer’s Disease and Patient Direct Costs

    Dec 1, 2025, 00:00

  • CO98 Epidemiological Study of Pulmonary Hypertension in Patients With Interstitial Lung Diseases (PH-ILD) in Gree A Retrospective Multicenter Study

    Dec 1, 2025, 00:00

  • HSD2 A Comprehensive Approach Including Mailed FITs and Nurse Navigation for Colorectal Cancer Screening

    Dec 1, 2025, 00:00

  • ISPOR Europe 2025: Powering Value and Access Through Patient-Centered Collaboration

    Dec 1, 2025, 00:00

  • CO12 APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes

    Dec 1, 2025, 00:00

  • EE464 Fecal Microbiota Transplantation for Irritable Bowel Syndrome With Constipation: A Decision-Analytical Analysis

    Dec 1, 2025, 00:00

  • P27 Predicting Treatment Effect on the Loss of Ability to Rise From Floor in Duchenne Muscular Dystrophy Using Individual Trajectories: An Application of Joint Modeling in FOR-DMD

    Dec 1, 2025, 00:00

  • MSR224 Which Generative AI Method Is Used for High Specificity? A Methodological Comparison From the Systemic Literature Review of the Burden of Influenza in France

    Dec 1, 2025, 00:00

  • RWD156 Real-World Evidence Study on Healthcare Resource Utilization (HCRU) Among Cancer Patients in the Helsinki and Uusimaa (HUS) Region, Finland

    Dec 1, 2025, 00:00

  • EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • EPH33 Burden of Bloodstream Infections in the United States: Incidence and Healthcare Resource Utilization 2022-2024

    Dec 1, 2025, 00:00

  • CO158 Leveraging Generative AI for Efficient Patient Safety Narrative Drafting: A Semaglutide Case Study

    Dec 1, 2025, 00:00

  • EE560 Introducing the Parameter Outcome Overview Plot: A New Addition to the Sensitivity Analysis Armory for Economic Models

    Dec 1, 2025, 00:00

  • RWD24 Association of Recurrences With Healthcare Resource Utilization in High-Risk Non-Muscle Invasive Bladder Cancer Patients Across Europe: A Real-World Survey

    Dec 1, 2025, 00:00

  • SA29 Design, Implementation, Data Analysis on the Time-Motions Studies: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE535 Impact of Indirect Treatment Comparison (ITC) Methodology on Cost-Effectiveness of Quizartinib in Acute Myeloid Leukemia (AML) in Canada and the United Kingdom (UK)

    Dec 1, 2025, 00:00

  • CO111 Evaluating Therapeutic Landscape in Radio-Iodine-Refractory–Differentiated Thyroid Cancer (DTC): A Bayesian Network Meta-Analysis of Clinical Efficacy

    Dec 1, 2025, 00:00

  • EE718 The Ongoing Challenge of Clostridioides Difficile Infection in Austria: Economic Evaluation of Two Recommended Treatment Pathways

    Dec 1, 2025, 00:00

  • HTA330 The Role of Health-Related Quality of Life in German HTA Decisions: An Analysis of G-BA Assessments From 2020-2024

    Dec 1, 2025, 00:00

  • P59 Challenges in Assessing Trade-offs Between Efficiency and Equity in the Use of Digital Health Applications for Stroke Care

    Dec 1, 2025, 00:00

  • EE491 Health Economic Evaluation Model for Pancreatic Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • EE507 Healthcare Resource Utilization in Patients With Hidradenitis Suppurativa Using Adelphi Real-World Data From EU5 and US

    Dec 1, 2025, 00:00

  • HSD90 Potential Operational Efficiencies of a Combination Influenza and COVID-19 Vaccine in US Pharmacies

    Dec 1, 2025, 00:00

  • CO68 Data Visualization of Treatment Patterns in Adults With BRAFV600E Mutant mNSCLC in Real-World Settings

    Dec 1, 2025, 00:00

  • EPH69 Effectiveness of HPV Vaccination Across Europe: A Comparative Analysis

    Dec 1, 2025, 00:00

  • HPR207 The Intercept of Real-World Evidence (RWE) Health Equity and Health Technology Assessment (HTA): A Structured Literature Review of Health Policy and Methodological Guidance

    Dec 1, 2025, 00:00

  • PCR86 Evaluation of the Effectiveness of a Naturalness Probe for Assessing Human- and Nonhuman-Generated COA Translations in Linguistic Validation Cognitive Debriefing Interviews

    Dec 1, 2025, 00:00

  • HSD62 Improving Patient Flow and Multidisciplinary Coordination in Urothelial Carcinoma: Insights From Bulgarian Oncologists

    Dec 1, 2025, 00:00

  • EPH211 Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy Patients in the Brazilian Public Health System: A Real-World Study

    Dec 1, 2025, 00:00

  • SA64 Mapping Disease-Specific Patient-Reported Outcome Measures (PROMs) to EQ-5D Utility Scores: A Systematic Review

    Dec 1, 2025, 00:00

  • HTA113 Disparities in Market Access of ATMPs: A Comparative Analysis of HTA Outcomes Across Europe

    Dec 1, 2025, 00:00

  • EE548 Incorporating Environmental Impact Into Health Economic Evaluations: A Review of Methodological Approaches and Practical Applications

    Dec 1, 2025, 00:00

  • MSR32 Applying the Delphi Method: A Scoping Review in Healthcare Decision Making and HEOR

    Dec 1, 2025, 00:00

  • HPR125 Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024

    Dec 1, 2025, 00:00

  • EE87 Budget Impact Analysis of Hyaluronic Acid Viscosupplementation for Knee Osteoarthritis in Colombia

    Dec 1, 2025, 00:00

  • SA69 Methods for the Economic Evaluation of Health Impacts of Climate Action: When, Why, and How Best to Use Them? A Literature Review

    Dec 1, 2025, 00:00

  • PCR189 Predicting Italian EQ-5D-3L Health State Utilities From UK Values: Validation of a Nonlinear Utility Adjustment Model Using Real-World Evidence

    Dec 1, 2025, 00:00

  • EE526 Impact of Budesonide-Glycopyrronium Formoterol Initiation on Healthcare Resource Utilization and Carbon Emissions in Patients With COPD in Spain: Insights From the ORESTES Study

    Dec 1, 2025, 00:00

  • HPR81 Evolution of National Price Negotiations for Pharmacy/Retail Medicines (Triparty Negotiations) in Sweden and Implications for Access

    Dec 1, 2025, 00:00

  • HTA6 A Decade in Decision Making: Reviewing Trends in STAS by NICE in Different Disease Areas

    Dec 1, 2025, 00:00

  • SA76 Pragmatic Advice to Improve Assessment Schedule of Preference-Based Measures of Health to Estimate Utilities in Clinical Trials

    Dec 1, 2025, 00:00

  • EPH191 Prevalence of Migraine in India: A Meta-Analysis With Subgroup Analyses by Population Type

    Dec 1, 2025, 00:00

  • RWD64 Director Primary Data Collection

    Dec 1, 2025, 00:00

  • HSD116 Treatment Patterns, Inadequate Disease Control, and Burden/Unmet Need Among Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program

    Dec 1, 2025, 00:00

  • HPR83 Evolution of Pharmaceutical Pricing and Reimbursement Agreements in Spain Over the Last 10 Years: Towards an Outcomes-Based Approach

    Dec 1, 2025, 00:00

  • EE564 Lessons From the NHS AI Awards: Experience of Evaluating AI Tools in Real-World Environments

    Dec 1, 2025, 00:00

  • EE598 Optimal Utilization of Robotic-Assisted Surgery in the NHS: A System-Level Economic Evaluation Model

    Dec 1, 2025, 00:00

  • PCR113 Health-Related Quality of Life Among People With Arthritis in Ireland

    Dec 1, 2025, 00:00

  • RWD183 Transplant Eligibility in DLBCL: A Real-World Analysis of German Hospital Billing Data

    Dec 1, 2025, 00:00

  • P23 Optimal Hemoglobin Thresholds for ICU Transfusion: A Target Trial Emulation in a Large Electronic Medical Record-Based Real-World Database

    Dec 1, 2025, 00:00

  • HTA304 Subsequent Treatments and NICE Appraisals for DLBCL: A Review of Committee Discussions

    Dec 1, 2025, 00:00

  • HTA67 CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?

    Dec 1, 2025, 00:00

  • MSR221 What Is the Value of Large Language Models for Improving Extraction and Interpretation of Efficiency Data From French Commission Dévaluation Économique et de Santé Publique (CEESP): Decisions on Breast Cancer Medications?

    Dec 1, 2025, 00:00

  • HTA81 Comparing Clinical Benefit Criteria in Health Technology Assessment of Oncology Drugs in the Netherlands and Europe: Driving Real Value or Inequal Access?

    Dec 1, 2025, 00:00

  • EE393 Economic Evaluations of Medical Interventions for Adult People Living With Obesity: Protocol for a Systematic Literature Review

    Dec 1, 2025, 00:00

  • PCR34 Burden of Transfusion in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Results From a Real-World Study in European Countries

    Dec 1, 2025, 00:00

  • RWD159 Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data

    Dec 1, 2025, 00:00

  • HSD9 Assessing the Impact of Technology-Powered, Pharmacy- and Nursing-Supported Direct Oral Anticoagulant Management

    Dec 1, 2025, 00:00

  • HPR161 Physicians’ Knowledge, Attitude, and Practice Regarding Medical Liability: A Study in Saudi Arabia

    Dec 1, 2025, 00:00

  • PCR190 Predicting Self-Efficacy in Managing Type 2 Diabetes: Results From a Low-Income, Less Educated Community of Quetta City, Pakistan

    Dec 1, 2025, 00:00

  • EE264 Cost-Effectiveness of Nivolumab Plus Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in Greece

    Dec 1, 2025, 00:00

  • EPH162 Modeling the Long-Term Bone Health Impact of TDF/FTC PrEP in Adolescent MSM

    Dec 1, 2025, 00:00

  • EE104 Budget Impact of an Ambulatory Minimally Invasive Surgical Treatment in an Italian Public Hospital

    Dec 1, 2025, 00:00

  • HTA166 Guidance for Real-World Evidence Generation for the Joint Clinical Assessment Process and Its Implications for Country-Specific HTA Body Acceptability

    Dec 1, 2025, 00:00

  • PCR18 Are Discrete Choice Experiment Results Robust to Omitted Attributes? Evidence From a Vaccine Study

    Dec 1, 2025, 00:00

  • EPH63 Disease Burden of MASH/MASLD Among People With Obesity in China, Japan, and EU5

    Dec 1, 2025, 00:00

  • RWD1 A Description of the Incidence and Burden of Hyperkalemia in Irish Hospitals 2022-2024

    Dec 1, 2025, 00:00

  • EPH50 Comparative Epidemiological Burden of Osteoarthritis in Eastern Central and Western Europe Based on the Global Burden of Disease Study 2021

    Dec 1, 2025, 00:00

  • SA2 A Patient-Level Simulation to Bridge Data Gaps in Cost-Effectiveness Modeling of B-VEC for Dystrophic Epidermolysis Bullosa

    Dec 1, 2025, 00:00

  • HTA192 IMF: The Innovative Medicines Fund or the Interim Medicines Fund?

    Dec 1, 2025, 00:00

  • PCR30 Beyond the Conversation: A Narrative Review of Cost-Informed Shared Decision Making and Its Impact on Medication Adherence in Chronic Conditions

    Dec 1, 2025, 00:00

  • PCR51 Concordance Between Patient and Physician Reporting of Symptoms for Metastatic Urothelial Cancer in Europe: A Real-World Survey

    Dec 1, 2025, 00:00

  • EE415 Establishing Robust and Adaptive Willingness-to-Pay Thresholds for Taiwan's National Health Insuran A Case Study of Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • CO178 Pegunigalsidase Alfa Elfabrio® as a Long-Term Enzyme Replacement Therapy in Adults With Fabry Disease: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE532 Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Antimicrobial Resistant Infections and Antibiotic Prescriptions in Greece

    Dec 1, 2025, 00:00

  • MSR95 Evaluating the Performance of a Supervised Artificial Intelligence Model in Screening Abstracts for Oncology-Focused Targeted Literature Reviews

    Dec 1, 2025, 00:00

  • MSR75 AI Time and Motion - Analysis of the Accuracy and Efficiency of AI for HTA-Standard SLRs

    Dec 1, 2025, 00:00

  • PCR103 Generalizability of Patient Preference Study Results: A Weight and Test Approach

    Dec 1, 2025, 00:00

  • SA33 Developmental Rehabilitation in Children With Autism: Utilization and Economic Burden in South Korea

    Dec 1, 2025, 00:00

  • MSR1 A Comparison of Methods for Missing Covariates in a Meta-Regression Using Data From a Systematic Review on Oral Epithelial Dysplasia

    Dec 1, 2025, 00:00

  • HPR93 Fair Pricing of Innovative Medicines From Definition to Application in CAR-T Cell Therapy

    Dec 1, 2025, 00:00

  • MSR27 Analysis and Characterization of Variations in Conceptual and Operational Definitions for GLP-1 Agonist Treatment Eligibility for Weight Management

    Dec 1, 2025, 00:00

  • HSD117 Trends and Economic Impact of Medication Errors in Public Hospitals of Eastern Region Ghana: A Retrospective Analysis From 2018 to 2024

    Dec 1, 2025, 00:00

  • EPH279 Years of Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Ukraine and in Kiev City, Lviv, and Cherkasy Regions

    Dec 1, 2025, 00:00

  • EE24 A Nonactive Implant for the Treatment of Chronic Gastro-esophageal Reflux Disease: A Cost-Effectiveness Evaluation From the Perspective of German Healthcare

    Dec 1, 2025, 00:00

  • HPR120 Implications of Recent US Policy Changes on Evidence Generation Requirements for Enabling Access to Medicines and Vaccines in Low- and Middle-Income Countries

    Dec 1, 2025, 00:00

  • EPH201 Quantification of the HPV-Attributable Cancer Mortality in Gree Years of Life Lost and Productivity Costs

    Dec 1, 2025, 00:00

  • EE205 Cost-Effectiveness Analysis of Inhaled Levodopa for Managing OFF Episodes in Patients With Parkinson’s Disease

    Dec 1, 2025, 00:00

  • EE547 Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions

    Dec 1, 2025, 00:00

  • EPH10 A Systematic Literature Review to Identify Risk Factors and Symptoms of Long COVID-19 in Adult Indian Patients

    Dec 1, 2025, 00:00

  • PCR216 Significant Burden of Chronic Obstructive Pulmonary Disease (COPD) on Health Status and Well-Being Persists Among Patients Experiencing One Severe or Two or More Moderate Exacerbations of COPD (ECOPD) and Their Caregivers (CGs)

    Dec 1, 2025, 00:00

  • PCR263 Valuing Health States When Transitioning From Stage 2 to Stage 3 Type 1 Diabetes in a Sample of the General Population in the United Kingdom

    Dec 1, 2025, 00:00

  • EPH98 Examination of Attitudes Towards Vaccinations Among the Hungarian Population

    Dec 1, 2025, 00:00

  • P36 The Value of the Health and Well-being Benefits of Healthcare Facilities Outdoor Spaces

    Dec 1, 2025, 00:00

  • EE190 Cost Comparison of Alternative Delivery Routes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) in the English National Health Service (NHS)

    Dec 1, 2025, 00:00

  • EPH32 Budget Impact of an Organized Screening Program for Chronic Kidney Disease in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • PCR43 Characterizing and Quantifying Impacts of Neuromyelitis Optica Spectrum Disorder (NMOSD) on Patients and Caregivers

    Dec 1, 2025, 00:00

  • Measuring the First Mover Advantage in US Biosimilar Markets

    Dec 1, 2025, 00:00

  • CO172 Nutritional Profile and Cost Evaluation of Elderly Patients in Home Care Within the Brazilian Private Health Sector: A Retrospective Study

    Dec 1, 2025, 00:00

  • PCR67 Effectiveness of Vonoprazan on Health-Related Quality of Life and Sleep Quality in Chinese Patients With Reflux Esophagitis: Post Hoc Analysis of the VIEW Study

    Dec 1, 2025, 00:00

  • SA22 Confirmation of Diagnosis Method for Robust Participant Selection in Direct-to-Patient Real-World Evidence Studies

    Dec 1, 2025, 00:00

  • EPH149 Integrated Sustainability Assessment of the Population-Based Colorectal Cancer Screening Program in Flanders

    Dec 1, 2025, 00:00

  • HSD28 COVID-19's Effects on Mental Health Services: The Effectiveness of Telepsychiatry and Challenges in Substance Use Disorders in the United States

    Dec 1, 2025, 00:00

  • CO47 Clinical Expert Opinion on the Impact of Vosoritide on Health and Function in Children With Achondroplasia

    Dec 1, 2025, 00:00

  • EE617 Procalcitonin-Guided Antimicrobial Stewardship for Sepsis and Lower Respiratory Tract Infections: A Budget Impact Analysis for the Perspective of the Patients in India

    Dec 1, 2025, 00:00

  • HTA211 Is NICE’s Proportionate Approach Achieving Its Objective: Analysis of Time to Access for Cost Comparison vs. Single Technology Appraisal

    Dec 1, 2025, 00:00

  • PCR211 Review of Patient Decision Aids for Psoriasis

    Dec 1, 2025, 00:00

  • HTA336 The Value Flower in Bloom: Emerging Recognition of Uncaptured Benefits in NICE HTA Decisions

    Dec 1, 2025, 00:00

  • EE59 Assessing the Cost-Effectiveness of Semaglutide 24 mg in the Management of People With Obesity and Knee Osteoarthritis in the UK

    Dec 1, 2025, 00:00

  • MSR212 Use of a Nonparametric Bayesian Method to Model Health State Preferences: An Application to UAE EQ-5D-5L Valuations

    Dec 1, 2025, 00:00

  • HPR123 Innovation in Off-Patent Competitive Environment: Key Learnings From Successes and Failures

    Dec 1, 2025, 00:00

  • HTA321 The Interim Acceptance and Ultraorphan Pathways in Scotland: An Update

    Dec 1, 2025, 00:00

  • PCR138 Increased Adherence to Biologic Therapies Leads to Lower All-Cause and Asthma-Related (HCRU) Costs in Severe Asthma

    Dec 1, 2025, 00:00

  • EPH36 Cardiovascular Event Rates and Mortality Among Secondary-Prevention Hypercholesterolemia Patients in Japan

    Dec 1, 2025, 00:00

  • EE114 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in Spain

    Dec 1, 2025, 00:00

  • RWD29 Characteristics of Real-World Data Landscape in Italy: A Scoping Review

    Dec 1, 2025, 00:00

  • HTA265 Patient Access Delays in Multi-Indication Medicines: A Review of Health Technology Assessment Timelines

    Dec 1, 2025, 00:00

  • PCR261 Utilizing the Patient-Specific Needs Evaluation for Data-Supported and Individualized Treatment (UNITE)

    Dec 1, 2025, 00:00

  • EPH186 Premature Cancer-Related Morbidity and Mortality in Israel: Years Lived With Disability and Years of Life Lost Productivity Costs

    Dec 1, 2025, 00:00

  • HPR57 Distributional Cost-Effectiveness Analysis Across the Globe: How Feasible Is It Really?

    Dec 1, 2025, 00:00

  • SA14 Assessing the Use of Artificial Intelligence in Publication-Grade Research: A Literature Review of Applications in HEOR

    Dec 1, 2025, 00:00

  • EE447 Evaluating the Societal and Economic Impact of Immunotherapy for Melanoma Treatment in Bulgaria

    Dec 1, 2025, 00:00

  • HTA346 Understanding the Impact of Equality and Equity Considerations on NICE Highly Specialized Technology (HST) Decision Making

    Dec 1, 2025, 00:00

  • PCR65 Diagnostic Odyssey of Patients With the Rare Immunodeficiency-Activated PI3 Kinase Delta Syndrome (APDS): Case Study With Expert Interviews and Patient Surveys

    Dec 1, 2025, 00:00

  • CO77 Comparative Efficacy of Ongericimab Versus Six PCSK9 Inhibitors in Treating Hypercholesterolemia or Mixed Dyslipidemia: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR253 Understanding Patient Priorities in Psoriasis Treatment: A Review of Key Decision-Making Drivers

    Dec 1, 2025, 00:00

  • EPH200 Quality of Life of Patients Living With Epilepsy in Hungary

    Dec 1, 2025, 00:00

  • EE250 Cost-Effectiveness of Familial Hypercholesterolemia Cascade Testing in Thailand: A Comparative Analysis of Exome vs. Long-Read DNA Sequencing

    Dec 1, 2025, 00:00

  • EE602 Optimizing Therapeutic Strategies for Multiple Sclerosis in Italy: A Budget Impact Analysis

    Dec 1, 2025, 00:00

  • MSR120 How Chinese Restaurants Can Help With Robust Preference Insights: A Novel Dirichlet Mixture Model to Account for Complex Heterogeneity in Individual Preference Weights

    Dec 1, 2025, 00:00

  • HTA182 How Will Patient Registry Data Play a Role in Joint Clinical Assessment (JCA) for Rare Diseases Learnings From National Health Technology Assessments (HTAs)?

    Dec 1, 2025, 00:00

  • CO139 Impact of Pharmacist-Led Interventions on Health-Related Quality of Life in Diabetic Patients: Assessment Using EQ-5D Domains and Visual Analog Scale

    Dec 1, 2025, 00:00

  • HTA135 Evaluating the Role of Societal Perspectives in the EU Joint Clinical Assessment Framework and in EU-27 Health Technology Assessment Guidelines

    Dec 1, 2025, 00:00

  • EPH269 Unlocking Insights in Prescription Data in England: The Power of the Prescribing Episode Statistics (PES) Database

    Dec 1, 2025, 00:00

  • CO59 Comparative Efficacy Safety and Discontinuation of Inhaled Levodopa for Patients With Parkinson’s Disease: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EE228 Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among At-Risk and High-Risk Adults in India

    Dec 1, 2025, 00:00

  • EE118 Burden of Illness and Healthcare Resource Utilization Among Patients Newly Diagnosed With Amyotrophic Lateral Sclerosis in the United States: A Retrospective, Observational, Cohort Design Study

    Dec 1, 2025, 00:00

  • MSR102 Exploring Artificial Intelligence's (AI's) Role in Literature Screening: A Comparative Analysis Paving the Way for More Efficient Evidence Synthesis

    Dec 1, 2025, 00:00

  • RWD48 DARWIN EU® Characterizing Clinically Recognized Hypertrophic Cardiomyopathy in Six European Countries: A Descriptive Analysis Using Real-World Data

    Dec 1, 2025, 00:00

  • EE730 Thecosystem: A Systemwide Health and Social Care Decision Analytical Model to Assess Population-Based Interventions for Older People’s Care in the UK

    Dec 1, 2025, 00:00

  • HTA9 A Matching-Adjusted Indirect Comparison (MAIC) of Rucaparib vs. Niraparib in the Maintenance Treatment of Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (aOC) After Response to First-Line Platinum-Based Chemotherapy

    Dec 1, 2025, 00:00

  • P3 Zoom In: Uncovering Clinical Nuance in Simplified Health Economic Model Structure Through Artificial Intelligence

    Dec 1, 2025, 00:00

  • EPH180 Pharosight: A Shiny-Based Interactive Platform With LLM-Enhanced Analyses and Predictive Modeling for Real-World Prescription Data

    Dec 1, 2025, 00:00

  • MSR146 Metamodels SHAP Analysis: Unearthing Data Interactions

    Dec 1, 2025, 00:00

  • CO91 Efficacy and Safety of Biologics to Treat Adults With Active Radiographic Axial Spondyloarthritis: Systematic Review and Bayesian Network Meta-Analysis

    Dec 1, 2025, 00:00

  • CO225 Systematic Literature Review (SLR) of Efficacy, Health-Related Quality of Life (HRQoL), and Safety of the First-Line (1L) Treatments of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Dec 1, 2025, 00:00

  • HSD80 Organizational Support in Adopting New Treatments for Generalized Myasthenia Gravis

    Dec 1, 2025, 00:00

  • EPH236 The Health Impact of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab Treatment for High-Risk Early Stage Triple-Negative Breast Cancer (eTNBC) in Türkiye

    Dec 1, 2025, 00:00

  • Understanding the Role of Clinical and Functional Needs in Home-Visit Nursing Effectiveness: Evidence From South Korea

    Dec 1, 2025, 00:00

  • EE715 The Impact of Real-World Standard-Dose Influenza Vaccine Effectiveness on the Cost-Effectiveness of High-Dose Influenza Vaccine: A Case Study in Japan

    Dec 1, 2025, 00:00

  • HPR62 Do Patient-Reported Outcomes Influence Drug Prices? Evidence From the Italian Pricing and Reimbursement System

    Dec 1, 2025, 00:00

  • MSR14 Advancing Multiple System Atrophy Diagnosis: Combining AI and Decision Analysis

    Dec 1, 2025, 00:00

  • CO159 Lipid-Lowering Prescription Patterns After a Nonfatal Acute Coronary Syndrome: The Impact of Real-World Evidence on Clinical Practice With LATINO-ACS 2.0

    Dec 1, 2025, 00:00

  • HTA311 Targeted Review of mITT vs. ITT Data in CAR-T Submissions

    Dec 1, 2025, 00:00

  • HTA291 Rising EAP Rejection Rates and Their Impact on Drug Access in France

    Dec 1, 2025, 00:00

  • HPR237 Value of the France Early Access Pathways: Highlighting Benefits for Patients and Industry Sponsors of the Novel Therapeutic Fosmanogepix Addressing High Unmet Clinical Needs in Invasive Fungal Infections

    Dec 1, 2025, 00:00

  • EE439 Evaluating the Costs of Perioperative Iron-Deficiency Anemia Management in China: A Comparison of Ferric Derisomaltose, Ferric Carboxymaltose, and Usual Care

    Dec 1, 2025, 00:00
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »